The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I/II trial of encorafenib, cetuximab, and nivolumab in microsatellite stable BRAFV600E metastatic colorectal cancer following progression on prior BRAF+EGFR targeted therapies.
 
Kelsey Pan
No Relationships to Disclose
 
Yunyu Baig
No Relationships to Disclose
 
Jason Willis
Honoraria - Bayer; Cor2Ed
Consulting or Advisory Role - Healios, K.K.
 
Arvind Dasari
Consulting or Advisory Role - HutcMed; Illumina/GRAIL; Personalis; SIRTIS; Takeda
Research Funding - Eisai (Inst); Guardant Health (Inst); Hutchison MediPharma (Inst); Merck (Inst); Natera (Inst); XENCOR (Inst)
Travel, Accommodations, Expenses - Hutchison MediPharma; Takeda
 
Alisha Bent
No Relationships to Disclose
 
Victoria Higbie
No Relationships to Disclose
 
Ryan Huey
Honoraria - Aptitude Health; Clinical Care Targeted Communications LLC; Vizient
Travel, Accommodations, Expenses - Clinical Care Targeted Communications LLC; Vizient
 
Bryan Kee
No Relationships to Disclose
 
Michael Lee
Employment - Johnson & Johnson/Janssen
Stock and Other Ownership Interests - Johnson & Johnson/Janssen
Consulting or Advisory Role - Bayer Health; BioNTech SE; Delcath Systems; G1 Therapeutics; Imvax; Johnson & Johnson/Janssen
Research Funding - Arcus Biosciences (Inst); Boehringer Ingelheim (Inst); EpimAb BioTherapeutics (Inst); Erasca, Inc (Inst); Merck (Inst); Repare Therapeutics (Inst); TriSalus Life Sciences (Inst); Xilis (Inst)
 
Christine Parseghian
No Relationships to Disclose
 
Maria Pia Morelli
No Relationships to Disclose
 
John Paul Shen
Stock and Other Ownership Interests - Agios; Syndax; Syndax
Consulting or Advisory Role - Engine Biosciences; NaDeNo Nanosciences
Research Funding - BostonGene; Celsius Therapeutics; Celsius Therapeutics
 
Scott Kopetz
Stock and Other Ownership Interests - Frontier Medicines; Lutris; Navire
Consulting or Advisory Role - Agenus; Amgen; AmMax Bio; Arcus Biosciences; AstraZeneca; AVEO; Bayer Health; BeiGene; Boehringer Ingelheim; Bridgebio; Bristol-Myers Squibb/Medarex; Carina Biotech; Clasp Therapeutics; Cytovation; Dewpoint Therapeutics; EMD Serono; Flame Biosciences; Frontier Medicines; Genentech; Harbinger Oncology, Inc; Ikena Oncology; Kestrel Therapeutics; Marengo Therapeutics; Merck; Mirati Therapeutics; Pfizer; Replimune; Revolution Medicines; Roche; SageMedic; SERVIER; Sibylla; T-Cypher Bio; Tachyon Therapeutics; XAIRA Therapeutics; Zentalis; Zentalis
Research Funding - Amgen; Boehringer Ingelheim; BridgeBio; Daiichi Sankyo; EMD Serono; Genentech/Roche; Guardant Health; Lilly; Pfizer; Zentalis
 
Van Morris
Consulting or Advisory Role - Bristol Myers Squibb Foundation; Incyte; Novartis; Regeneron; Scandion Oncology
Research Funding - Apollo Therapeutics (Inst); Bicara Therapeutics (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); Pfizer (Inst); Redx Pharma (Inst); Sumitomo Pharma Oncology (Inst)